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Abstract 
This dissertation was written as part of the LLM in Transnational and European 
Commercial Law, Mediation, Arbitration and Energy Law at the International Hellenic 
University.  
In this dissertation, there will be analyzed the phenomenon of parallel trade in 
pharmaceuticals, which is based on the principle of parallel trade in pharmaceuticals, 
according to Articles 34, 35 and 36 TFEU, as mentioned in the first chapter.  
Moreover in the second chapter, there will be an analysis for the pharmaceutical 
market and the parallel trade in pharmaceutical sector. In the same chapter, there will 
be mentioned which is the importance of intellectual property rights in pharmaceutical 
industry and, also, which is the meaning of Exhaustion of Intellectual Property Rights. 
The subsequent chapter refers to Articles 101 and 102 TFEU and the restraints in 
parallel trade of pharmaceutical products, which is an issue examined in many ECJ law-
cases, some of which are mentioned to the fourth chapter. Finally, the last chapter has 
to do with positive and negative aspects of parallel trade in pharmaceuticals. 
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Introduction 
Free movement of goods is one of the most important principles that has been 
established in European Union, according to Articles 34, 35 and 36 of the Treaty on the 
Functioning of the European Union. This is why the same Treaty provide a lot of 
provisions, such as tax provisions or provisions regarding custom duties, which support 
free circulation of goods and healthy competitive environment between Member 
States. Depending on these Articles, it has to be mentioned that parallel trade is a very 
common phenomenon in pharmaceutical market as well, something that has many 
effects not only in patients, but, also, in health security systems and pharmaceutical 
companies around European Union.  
More analytically, parallel trade in pharmaceutical sector started at around 1970, but 
was regulated for the first time in the provisions of the Treaty Establishing the 
European Community and especially in Articles 28, 29, 30 of the above mentioned 
Treaty1. One of the most important reasons that lead to the expansion of parallel trade 
in pharmaceuticals is the fact that in every Member State there is a different price 
even for the same product due to the financial ability of the consumers or the 
regulations of the national health authorities of each country. For example, many 
times pharmaceutical companies prefer to sell their medicinal products in another 
Member State, where consumers can afford more expensive drugs, in order to gain 
higher profits.  
To continue with, until today, there has been formulated a specific framework of the 
pharmaceutical market in European Union which follows the general principle of free 
circulation of goods within Member States. In more detail, because of the fact that 
each Member State had its own regulations for the authorization, marketing and sell of 
a pharmaceutical product, competent European Authorities decided that there should 
be a specific authorization system for the whole European Union in order to make the 
process easier for all the traders. On this basis, there was established European 
                                                 
1 Ηancher Leigh “The EU pharmaceuticals market: parameters and pathways” (published 2010) ch 15, 635 
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Medicines Evaluation Agency (EMEA) that is responsible for all the relevant 
procedures, for all the Member States alike2. 
At this point, it should be, also, mentioned that intellectual property rights is one of 
the biggest assets of a pharmaceutical company, because they invest not only a lot of 
money but also time and intellectual property rights play the role of a motivation for 
them. This is why it should be examined which is the role of exhaustion of IPRs in the 
expansion of parallel trade in consumer goods in general and why it allows parallel 
trade of pharmaceutical products in European Union being a common phenomenon 
within Member States. It is very important to mention, as well, that because of the fact 
that parallel traders gain great profits, the manufacturers of the pharmaceutical 
products sometimes try to restrain traders by parallel importing their products using 
many methods based on Articles of TFEU. However, it should be examined whether 
these methods are legal or not. Regarding this issue, there are many ECJ law-cases that 
have to do with EU Competition Law Rules and parallel trade. In more detail, in these 
cases, as analysed in this paper, it was examined whether some obstacles put in 
parallel traders infringe the provisions of Articles 101 and 102 TFEU3, according to 
which no obstacles should be set in trading between Member States and nothing 
should prevent competition within EU internal Market. 
To sum up, it is without doubt that parallel trade not only, in general, but also in 
pharmaceuticals specifically, is a very controversial issue that has positive and negative 
aspects as well. The question which will be the situation regarding parallel trade in 
pharmaceuticals in some years remains unanswered, because, undoubtedly, in these 
circumstances of financial crisis, traders try to find the most profitable way to sell their 
products. However, despite the fact that there are many regulations, directives and 
agreements between Member States and even more law cases, trying to clarify the 
legal framework of parallel trade in pharmaceutical products, there are still unclear 
issues. It remains to be seen which exactly will be the legal framework of parallel trade 
in pharmaceutical sector in the next decades and also which will be the criteria for the 
adoption of new principles regarding this issue. 
                                                 
2 Kyle Margaret, “Parallel trade in pharmaceuticals: Firm responses and competition policy” (published 
2009), 340 
3 Articles 101 and 102 TFEU 
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These crucial subjects will be analysed in this paper, in order to examine in which way 
parallel trade of pharmaceutical products functions in European Union nowadays.  
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1. Free movement of goods in EU Internal Market 
To start with, in this paper has to be analyzed the principle of free movement of goods, 
according to Articles 34, 35 and 36 Treaty on the Functioning of the European Union, 
which allows the parallel trade of consumer goods in internal market and prohibits 
obstacles in cross-border trade between Member States. As a result it is obvious that 
the term “goods” plays a major role in parallel trade within European Union. 
Analytically, “goods” are consumer products that have a monetary value and can be 
bought and sold4. 
1.1. Article 34 and 35 TFEU 
1.1.1. Analysis of Article 34 and 35 TFEU 
It has to be mentioned that single EU Internal Market is one of the most important 
elements of European Union, because in this way, consumer goods can freely move 
within the European Union limits. In this framework, parallel trade is allowed within 
European Union especially according to Articles 34 and 35 TFEU5.  
More specifically, according to Article 34 TFEU “Quantitative restrictions on imports 
and all measures having equivalent effect shall be prohibited between Member 
States”.6 In practice, it means that Member States shall not make harder the process of 
importation of goods from another Member State and that there should be no 
quantitative restrictions or measures with equivalent effect, direct or indirect, 
regarding the transportation of goods between Member States. For example, it is not 
acceptable, according to Article 34 TFEU, that a Member State asks for an extra license 
that other Member States do not ask for in order to accept the importation of foreign 
consumer goods. In other words, there should be no obstacles to trade between 
Member States, otherwise, the objective of a single market in European Union shall 
not be implemented.  
More specifically, Articles 34 and 35 TFEU do not allow the existence of QRs and 
MEQRs in cross border trade between Member States, even directly or indirectly. It 
                                                 
4 Alina Tryfonidou, “Free movement of goods” (published 16 December 2014), available at 
<https://login.westlaw.co.uk> 
5 Kyle Margaret, “Parallel trade in pharmaceuticals: Firm responses and competition policy” (published 2009), 340 
6 Article 34 TFEU 
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has to be mentioned that the definition for “MEQRS” is different according to the 
provision that includes it. For our purposes, the term “MEQRS” has to do with any 
measure that Member States adopt and as a consequence of that, parallel trade 
becomes even more difficult7. Due to this definition which is not precise, there are 
many ECJ law cases interpreting it, some of which are mentioned below.  
1.1.2. Dassonville Case 8/74 
In connection with the above mentioned, there have been many disputes and 
respective case law by the European Court of Justice regarding the meaning of 
equivalent effect of measures, such as the Case 8/74 Procureur du Roi v Benoit and 
Gustave Dassonville8 (1974), which is one of the most important cases regarding this 
issue. This EU Law case has to do with the fact that according to Belgian Law 
Dassonville was required to have a certificate in order to sell Scotch whisky in Belgium, 
but Dassonville didn’t get such certificates from France, where he bought these goods 
for sale. To analyze it, Belgian Law made the sale of the consumer goods harder for 
Dassoville, as in France there was no respective measure, which means that 
Dassonville could easier sell Scotch whisky there. The controversial issue was about 
whether provisions of Belgian Law infringed Article 34 TFEU, according to which no 
restrictions, direct or indirect, are allowed in the framework of trade between Member 
States. ECJ decided that, verily, Belgium should not have stated an obstacle to trading, 
as it is a measure with equivalent effect to restrictions in quantity. The fact that the 
obstacle is not very big, is not a criterion for the examination of this issue9, because it 
undoubtedly prevented free circulation of consumer goods.  
1.2. Article 36 TFEU 
1.2.1. Analysis of Article 36 TFEU 
 
However, according to Article 36 TFEU there are some circumstances such as “…public 
morality, public policy or public security; the protection of health and life of humans, 
                                                 
7 See Alina Tryfonidou, “Free movement of goods” (published 16 December 2014), available at 
<https://login.westlaw.co.uk> 
8 Case 8/74, Procureur du Roi v Benoit and Gustave Dassonville [1974]  
9 See Case 8/74, Procureur du Roi v Benoit and Gustave Dassonville [1974] 
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animals or plants; the protection of national treasures possessing artistic, historic or 
archaeological value; or the protection of industrial and commercial property…..10” that 
could lead to prohibitions or just restrictions on free movement of goods in European 
Union11.  
Regarding the topic of this paper, the most important justification for the prohibition 
of cross-border trade between Member States is the “..protection of industrial and 
commercial property…12“. In any case, the protection of intellectual property rights, in 
general, shall not in any case be a justification for the prohibition of trade between 
Member States. In other words, from the above mentioned, it is understood that 
despite the fact that intellectual property is a very serious issue, the principle of free 
movement of goods shall not be affected and for this reason many directives try to 
regulate it in order to ensure the proper functioning of the single internal market of 
European Union.  
More specifically, in the framework of parallel trade in pharmaceuticals, it is observed 
that Article 36 TFEU is sometimes used by Member States that want to ensure that the 
production of pharmaceutical products by domestic pharmaceutical companies shall 
not be harmed. However, this behaviour is most of the times opposed to the basic 
principles of the Treaty on the Functioning of the European Union. The reason is that 
that the owner of the intellectual property rights shall not prevent others from 
importing the pharmaceutical product to any other country of the European Union 
after it was first marketed, because after the first distribution of the pharmaceutical 
product, all industrial property rights are exhausted. Based on the fact that the most 
important rights in pharmaceutical industry are the patents and the trademarks, the 
exhaustion of IPRS plays a vital role in parallel trade of pharmaceutical products and it 
will be analysed below in this paper. 
1.2.2. Cassis De Dijon Case 120/78 
Regarding Article 36 TFEU, it has to be mentioned that there are many law-cases, 
trying to specify the meaning of this provision. One of these is the case Rewe-Zentral 
                                                 
10 Article 36 TFEU 
11 European Commission, Free movement of goods: Guide to the application of Treaty provisions governing the free 
movement of goods (Luxembourg: Publications Office of the European Union, 2010) ch 6, available at 
<ec.europa.eu/DocsRoom/documents/104/.../1/.../pdf> 
12 See Article 36 TFEU 
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AG v Bundesmonopolverwaltung, known as Cassis De Dijon Case 120/7813. The 
importance of this law case has to do with the fact that it interpreted the term 
”MEQRS” stating that if the marketing of a good is allowed in a certain Member State 
without extra requirements, the same will happen to all Member States. An extra 
requirement could be for example, a certificate mandatory for the trade of a product. 
This decision was the first time of application of the principle of mutual recognition14. 
This law case has to do with the sale of a specific type of the liqueur “Cassis de Didjon” 
produced in France with a percentage of 15% to 20% alcohol, whereas in Germany 
there was a law provision, according to which this type of liqueurs should have at least 
25% of alcohol. Of great importance is that despite the fact that the competent 
authorities allowed the importation of goods, the marketing of the specific goods was 
prohibited in Germany and due to this prohibition the importer stated that it was a 
measure with equivalent effect to quantitative restriction in the framework of trade 
between Member States. According to the above mentioned, ECJ decided that the 
German law provisions set measures, that are equivalent to quantitative restrictions in 
imports, something that infringes the principle of free movement of goods and 
especially, Articles 34-36 TFEU, even if the same restrictions are applied not only to the 
goods imported, but, also, to the consumer goods produced in this country. In this law 
case the protection of public health and the protection of the buyers incurring 
commercial practices that are not fair, were not accepted as a reason for the 
application of such restrictive measures to cross-border trade. As a result, we 
understand that the application of Article 36 TFEU should be examined every time, 
because it depends on the circumstances of each case. 
1.3. Other Articles of TFEU 
1.2.1. Analysis of Article 30 TFEU 
Article 30 TFEU plays a vital role in the trade between Member States, as it prohibits 
custom duties and other similar charges on transactions between Member States. 
Relating to this issue, there is a huge range of ECJ and other Courts decisions which, 
                                                 
13 Case 120/78, Rewe-Zentral AG v Bundesmonopolverwaltung [1978] 
14 See Alina Tryfonidou, “Free movement of goods” (published 16 December 2014), available at 
<https://login.westlaw.co.uk> 
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furthermore, provide the interpretation of the term CEE defining that CEE are all the 
charges applying to import or export of goods crossing borders. This kind of charges is 
not allowed as the effect of them is that foreign goods become even more expensive, 
and as a result, domestic goods are cheaper and more attractive for the consumers. In 
other words, CEEs harm the implementation of the principle of free movement of 
goods15.  
1.2.2. Commission of the European Communities v Italian Republic 24/68 
Regarding Article 30 TFEU there is a case known as Commission of the European 
Communities v Italian Republic 24/6816. Analytically, Italy imposed a tax - known as 
statistical levy - before the application of the EEC Treaty, on the imported and 
exported goods. This tax depended on the weight of the goods, meaning that if a good 
was heavier than another, the tax for it would be heavier. However, Commission 
decided that this tax was a measure equivalent to customs, something that was 
prohibited at that time according to Article 16 of the EEC Treaty, irregardless of how 
heavy was the tax. Commission justified her decision mentioning that according to the 
provisions of the EEC Treaty such a charge is not allowed, because it is contrary to the 
principle of free movement of goods and there are no justifications that the Treaty 
states or that a Member State could use in order to overlook the relevant provisions of 
the Treaty. Finally, the Commission stated that there may be cases that Member States 
could be charged with an amount of money - which is not a tax – when a service is 
needed in the framework of import or export of goods, but, undoubtedly, this charge 
may be allowed in specific services that are irrespective of Articles 9, 12, 13 and 16 of 
the EEC Treaty. According to the above mentioned, the defendant mentioned that 
Commission’s decision was wrong, because that the specific charge cannot be 
characterized as a charge with equivalent effect to custom duties as this charge is 
imposed both in imports and exports of not only foreign, but, also, of domestic goods, 
which means that there is  no discrimination. The defendant, moreover, stated that 
Commission should not have judged the specific charge, dividing it into two different 
charges, one to the import and one to the export of goods. The answer to this 
                                                 
15 See Alina Tryfonidou, “Free movement of goods” (published 16 December 2014), available at 
<https://login.westlaw.co.uk> 
16 Case 24/68, Commissioner of the European Communities v Italy 24/68 [1996] ECR 193 
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argument was that it is irrelevant weather this charge is one general or two different 
charges, because in any case it has an effect on the free movement of goods.  
Based on the above mentioned provision of Article 30 TFEU, it should be mentioned 
again that when a charge is characterized as CEE it is any case unlawful and there is no 
possibility of levying such a charge lawfully. However there are some charges that are 
not characterized as CEE and for this reason Member States charge others lawfully and 
especially, charges that have to do with administrative services or inspection 
mandatory according to the European Law provisions or internal taxation, according to 
Article 110 TFEU. According to this issue, there is a case known as Commission of the 
European Communities v Germany 18/8717, which has to do with a charge imposed by 
Germany upon the import of live animals. The decision was that this specific charge 
was justifiable as charge for a specific economic service, which is lawful under EU Law. 
1.2.2. Analysis of Article 110 TFEU 
Although, Article 110 TFEU states that Member States can freely tax all goods 
marketed within their Territory, they are not allowed to tax directly or indirectly goods 
imported in their countries, which is something of great importance for the free 
circulation of goods within European Union. To analyse it more, when a Member State 
imposes a higher tax in foreign goods imported in their countries, the price of these 
goods becomes even higher and as a result, consumers prefer to buy similar domestic 
goods which are cheaper. Article 110 TFEU states taxation prohibitions in both 
paragraphs18.  
In more detail, according to Article 110 (1) TFEU “..No Member State shall impose, 
directly or indirectly, on the products of other Member States any internal taxation of 
any kind in excess of that imposed directly or indirectly on similar domestic 
products..19”. It means that discrimination in taxation of goods imported - in the 
interest of domestic goods – is not allowed, and there should be no justifications, such 
as the origin of goods or the frequency of import especially in direct taxation. 
However, there are some certain objective reasons why indirect taxation could lawfully 
                                                 
17 Case 18/87, Commission of the European Communities v Germany [1988] E.C.R. 3595 
18 See Alina Tryfonidou, “Free movement of goods” (published 16 December 2014), available at 
<https://login.westlaw.co.uk> 
19 Article 110 (1) TFEU 
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be imposed by a Member State in imported foreign goods. Regarding this issue, there 
is a law-case known as Chemial Farmaceutical SpA v DAF SpA 140/79, which has to do 
with an industrial policy justification. Analytically, in this case there was a difference in 
taxation between denatured synthetic alcohol and denatured alcohol, but the Court 
decided that it was not opposed to Article 95 of the EEC Treaty, because the same 
measure was applied to the two categories of alcohol imported into Italy by all 
Member States. In any case, imports of synthetic alcohol into Italy were limited and 
the lower taxation of domestic goods was in favour of Italian production of denatured 
ethyl alcohol from sugar-beet molasses20.  
Furthermore, according to Article 110 (2) TFEU “….no Member States shall impose on 
the products of other Member States any internal taxation of such a nature as to 
afford indirect protection to other products..21”. It means that it is not allowed to tax 
differently foreign imported and domestic goods which are in competition, meaning 
goods that consumers can replace one another, because in this way consumers choose 
the cheaper product, based on the price of it.  
From the above mentioned, it is obvious that Articles 110 (1) and 110 (2) TFEU have 
similar meaning. The difference between them is that Article 101 (1) TFEU has to do 
with products similar the one with another, whereas Article 110 (2) TFEU has to do 
with products that are in competition with each other. As a result, when there is an 
infringement of Article 110 (1) TFEU, the Member State shall impose equal tax to 
similar domestic and foreign goods and when the infringement has to do with Article 
110 (2) TFEU, the Member State should avoid protecting domestic products by 
imposing lower taxes in comparison with foreign goods that are in competition with 
them22. 
1.4. Conclusion 
To sum up, it is without doubt that the principle of free movement of goods is one of 
the most important principles in European Union that helps the uniformity and 
integration of EU Internal Market, according to Articles 34, 35 and 36 TFEU. However, 
                                                 
20 Case 140/79, Chemial Farmaceutical SpA v DAF SpA [1981] E.C.R. 1 
21 Article 110 (2) TFEU 
22 See Alina Tryfonidou, “Free movement of goods” (published 16 December 2014), available at 
<https://login.westlaw.co.uk > 
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there are also other provisions of Treaty on the Functioning of the European Union 
which support the integration of single European Union Market, such as tax provisions 
or provisions regarding custom duties in case of import or export of goods within 
European Market. As it will be analyzed below in this paper, the principle of free 
movement of goods is the basis of parallel trade in pharmaceuticals within European 
Union. For these reasons and because of its importance, there are many cases that ECJ 
dealt with, trying to specify the meaning of the principle of free movement of goods 
within European Union and generally, of the framework of single EU internal market.   
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2. Parallel trade in pharmaceuticals 
In this Chapter will be analyzed not only the general meaning of parallel trade, but, 
also, the more specific provisions of parallel trade in pharmaceuticals, a phenomenon 
which is connected with the existing conditions applying to pharmaceutical market in 
EU. Moreover, another very important issue mentioned here is the major role that 
intellectual property rights play in pharmaceutical industry and finally, the principle of 
exhaustion of intellectual property rights that has to do with the legal framework of re-
importation of goods in general and also in pharmaceuticals. 
2.1. General meaning of parallel trade  
The general meaning of the term “parallel trade” is the resale of consumer goods in 
other markets without the authorization of the original owner of the intellectual 
property rights that have to do with these goods, meaning the trademark, patent, 
design or copyright. In more detail, parallel importing refers to the sale of the same 
good in different markets at different prices23. This phenomenon is something well 
known in European Union. Ιn practice, when the regulations allow it and the 
movement of consumer goods is economically affordable, firms choose parallel trade 
and in this way, make bigger profits, because they sell low-price consumer goods in 
high-price countries24. Additionally, parallel importing encourages not only 
competition between Member States, but, also, the free movement of goods, 
according to Article 34 TFEU, while, simultaneously, gives the opportunity to 
consumers all over European Union to choose the cheapest between more products of 
the same quality. However, there are people who think that parallel trade harms 
intellectual property rights and prevents companies in Member Stages to investigate in 
new patents and qualitative products25, because companies try to produce cheaper 
                                                 
23 Kyle Margaret, “Parallel trade in pharmaceuticals: Firm responses and competition policy” (published 2009), 339-
346 
24 Bart Thomas, “Parallel trade of pharmaceuticals: a review of legal, economic and political aspects”, Value in 
health(Volume ii, Number 5, 2008) 996 
25 Arfwedson Jacob, “Re-importation (Parallel Trade) in Pharmaceuticals”, Institute for Policy Innovation (IPI Center 
for Technology Freedom, 2004) 1  
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products at regular intervals in order to gain profit by selling their goods in other 
Member States. 
2.2. The incentives for re-importation of consumer goods 
Parallel importing has to do with the fact that someone can find the same 
consumer good at different prices in various markets. In more detail, companies 
choose “parallel trade” when the expenses of transportation and sale of consumer 
goods in foreign countries are lower than the price differential26 and in this way they 
gain profit easily and of course, lawfully applying the basic principle of free movement 
of goods within European Union.  
However, there are many reasons that lead to the expansion of parallel trade 
between Member States. First of all, the owner of the intellectual property rights has 
the ability to sell the good in different prices according to the needs and the financial 
ability of every market, meaning that the price of the goods is adapted to the special 
circumstances of every Member State. Furthermore, it is very important that 
Intellectual Property Rights protection is different in every country and for this reason 
there may be a case that a product is no longer under protection, because of the 
expiration of the patent, whereas the same product is protected in another country 
with different jurisdiction. In this case, in the country which applies the shorter period 
of patent protection, a company could sale generic products and in this way reduce 
the price of the patented product. Moreover, the different circumstances of every 
country and the standard of living may influence the price of the consumer goods, as 
well as the fact that each government regulates in different way the prices of 
consumer goods. As a result, it will be a motivation for parallel trade of consumer 
goods in European Union. Furthermore, it is without doubt that tax system may cause 
price differentials, because companies try to gain profits using different sales 
strategies and finally, a circumstance leading to price differentials is the variation of 
inflation rates depending on the regulation and the circumstances of each country27. 
So, it goes without saying that price differentials may often be a motivation for the 
                                                 
26 See Arfwedson Jacob, “Re-importation (Parallel Trade) in Pharmaceuticals”, Institute for Policy Innovation (IPI 
Center for Technology Freedom, 2004) 5 
27  See Arfwedson Jacob, “Re-importation (Parallel Trade) in Pharmaceuticals”, Institute for Policy Innovation (IPI 
Center for Technology Freedom, 2004) 5 
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traders to choose parallel trade in order to gain profits in an environment, different 
from the country of origin, which is of greatest benefit for them. 
2.3. Parallel trade in pharmaceuticals 
2.3.1. Meaning of parallel trade in pharmaceuticals 
As mentioned, parallel trade in general has as main goal the maintenance of the unity 
of EU internal Market and of the competitive environment between Member States. 
More specifically, parallel trade in pharmaceuticals - based on the free movement of 
consumer goods, as regulated by European Union - has to do with the parallel 
importing of pharmaceutical products in Member States, something which has specific 
implications not only to patients, but also to the health security systems and the 
pharmaceutical companies as well. Parallel trade in pharmaceuticals started at around 
1970, without being specially regulated. However, parallel trade was then established 
as basic principle of European Union and is until now depended on the free movement 
of goods, mentioned, initially, in the provisions of Articles 28, 29 and 30 of the Treaty 
Establishing the European Community28.    
2.3.2. Pharmaceutical market in EU 
In connection with the above mentioned and in order to examine the expansion of the 
phenomenon of parallel trade especially in pharmaceutical sector, it has to be 
analyzed which are the existing circumstances in the market of pharmaceutical 
products within European Union. As it is known, there are very strict rules regarding 
the production and the authorization of drugs not only in every country distinctly, but, 
also, in European Union. At this point, it is very important to be mentioned that 
because of the fact that every Member State had its own rules regarding the 
production and sale of pharmaceutical drugs, something that made harder the parallel 
trade in pharmaceuticals around European Union, there has been many attempts to 
make the procedures easier and more equable29. More specifically, the application of 
Directives and the establishment of European Medicines Evaluation Agency (EMEA) 
                                                 
28 Ηancher Leigh “The EU pharmaceuticals market: parameters and pathways” (published 2010) ch 15, 635 
29 Claudia Desogus, “Competition and Innovation in the EU Regulation of Pharmaceuticals: The case of parallel 
trade” (published 2013) ch 1, 39-42 
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were the most important steps for the achievement of uniformity30, because, in this 
way, pharmaceutical companies that do business within European Union follow a 
certain authorization procedure for the whole EU Internal Market, saving in this way 
money and time.  
However, the most difficult part for the uniformity of pharmaceutical market in 
European Union is the fact that in every Member State there may be a different price 
even for the same pharmaceutical product. It has to do not only with the financial 
ability of the consumers, but, also, with the different regulations that every country 
has. As a result of the existence of mechanisms that control the prices in every 
country, pharmaceutical companies choose parallel trade as the most advantageous 
solution which, as above mentioned, is based on the principle of free movement of 
goods, according to Articles 34, 35 and 36 TFEU and is lawful as it depends on one of 
the basic principles of European Union31. 
2.4. The role of intellectual property rights in parallel trade of pharmaceuticals  
2.4.1. Importance of intellectual property rights in pharmaceutical industry 
It is without doubt that intellectual property rights such as patents and trademarks 
play a vital role for pharmaceutical companies in general and are of great value for 
them. The reason for this fact is that every pharmaceutical company around the world 
investigates in new pharmaceutical products, something which needs not only much 
money, but, also, enough time in order to produce a new innovative drug. As a result 
and based on the great importance of the field of Research and Development for a 
pharmaceutical firm, it is proved why intellectual property rights is the biggest asset of 
a pharmaceutical firm32. At this point and in order to emphasize the fact that 
intellectual rights are the most important assets for pharmaceutical companies, it 
                                                 
30 Desogus Claudia “Competition and innovation in the EU regulation of pharmaceuticals: the case of parallel trade” 
(published 2010), available at <http://www.andychinart.com/competition-and-innovation-in-the-eu-regulation-of-
pharmaceuticals-the.pdf> 
31 See Claudia Desogus, “Competition and Innovation in the EU Regulation of Pharmaceuticals: The case of parallel 
trade” (published 2013) ch 1, 39-42 
32 Alberto Heimler, “The pharmaceutical industry and parallel trade”  
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should be mentioned that except for the registered IPRS, there are, also, IPRS, for 
which there is no need for registration33, such as copyright.  
Here will be analysed the meaning of patent, which is the most important kind of 
intellectual property right in pharmaceutical industry. To start with, patents are the 
main element for a pharmaceutical company that invests in new drugs and researches, 
in order to develop new qualitative pharmaceutical products34. The reason, especially 
for the importance of patents is that on the basis of patent protection the owner of 
the patent has a long period of exclusivity on the drug35. Of course, the importance of 
patent protection has to do with duration of the period that a patent is an exclusive 
right of a specific proprietor. At this point, it is very crucial to mention that according 
to international agreements the period of exclusivity of a patent is twenty (20) years 
from the date that the proprietor applied for a patent36. Someone could say that a 
patent is a reward for pharmaceutical companies that choose to investigate in new 
drugs and spend money for that aim, instead of trying to save money and sell cheap 
drugs of poor quality to patients around the world.  In other words, when a company 
produces a new drug, it applies for a patent, in order to ensure that it has a monopoly 
position in the pharmaceutical industry regarding the specific product37. 
However, there are, of course, not only positive, but, also, negative aspects of patents 
in pharmaceutical industry. More analytically, the strict policy regarding patents may 
sometimes be undue, but on the other hand patent system around the world gives 
always to pharmaceutical industry players a motivation to try harder and to aim at 
qualitative and innovative products38. Moreover, another interesting aspect of the 
protection of patents, as intellectual property rights, is that through patent system it is 
ensured that the proprietor will give the relevant information regarding his patent to 
the public, whereas someone who has not applied for a patent may keep it 
confidential. 
                                                 
33 Atkinson, Jonathan and Rachel Jones "Intellectual property and its role in the pharmaceutical industry" (published 
2009) 1547 
34Atkinson, Jonathan and Rachel Jones "Intellectual property and its role in the pharmaceutical industry" (published 
2009) 1547 
35 Alberto Heimler, “The pharmaceutical industry and parallel trade”  
36 Future science, “Intellectual property and its role in the pharmaceutical industry” (published 2009) 1547 available 
at < https://www.future-science.com/doi/pdf/10.4155/fmc.09.138> 
37 See Future science, “Intellectual property and its role in the pharmaceutical industry” (published 2009) 1547 
available at < https://www.future-science.com/doi/pdf/10.4155/fmc.09.138> 
38 See Alberto Heimler, “The pharmaceutical industry and parallel trade”  
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2.4.2. Exhaustion of IPRS 
The legal framework of re-importation of goods has to do with the principle of 
exhaustion of intellectual property rights that is known internationally. It means that 
when a good with a specific trademark, for example, is sold in a market by the 
intellectual property right owner, he cannot prohibit the distribution of the good, 
because there is an exhaustion of his intellectual property rights39. In connection with 
the above mentioned, in the framework of parallel trade the owner of the intellectual 
property right may not give his permission in order for the goods to be resold within 
Members States40. However, the procedure is completely lawful in the framework of 
free movement of goods, because there is an exhaustion of IPRS. 
To start with, before analysing the re-importation especially in pharmaceuticals, it has 
to be examined which is the relationship between exhaustion of intellectual property 
rights and parallel trade. First of all, it has to be mentioned that all ideas are protected 
as intellectual property rights41. For example, an invention is protected as a patent. As 
a result, if someone is the owner of a patent, he can prohibit the reproduction, sell and 
distribution for the period of protection, which in most cases is twenty (20) years. The 
same happens when someone is the owner of a trademark or copyright42. As 
aforementioned, the exhaustion of intellectual property is the basis of the parallel 
trade. It happens, because, for example, a patent owner cannot control the 
distribution of a patented good after the sale of the good in the first Member State 
within the EU internal market with his consent as the proprietor of the intellectual 
property right. Analytically, depending on the applicable law, there are three ways of 
exhaustion of intellectual property rights: 
 Νational exhaustion of intellectual property rights that has to do with the 
exhaustion of the trademark, patent or copyright right on the market that the 
goods were sold, meaning that parallel importing in the country would lead to 
                                                 
39 See Bart Thomas, “Parallel trade of pharmaceuticals: a review of legal, economic and political aspects”, Value in 
health(Volume ii, Number 5, 2008) 996 - 1005 
40 See Kyle Margaret, “Parallel trade in pharmaceuticals: Firm responses and competition policy” (published 2009), 
345 
41 Health Christopher, “Parallel imports and international trade” (published 1997), available at  
<http://www.wipo.int/mdocsarchives/ATRIP_GVA_99/ATRIP_GVA_99_6_E.pdf> 
42  See Arfwedson Jacob, “Re-importation (Parallel Trade) in Pharmaceuticals”, Institute for Policy Innovation (IPI 
Center for Technology Freedom, 2004) 5 
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infringement of the relevant intellectual property right. In this case, intellectual 
property rights are linked with the country and for this reason, they are limited 
within the geographical limits of each country. It happens in states, where 
according to applicable law there is a “principle of national exhaustion”. 
 Regional exhaustion of intellectual property rights means that the IPRS are 
exhausted to a broader market, consisting of different countries. 
 International exhaustion of intellectual property rights means that there is an 
exhaustion of IPRS if the good is launched in any market worldwide. More 
analytically, in cases where the “principle of international exhaustion” is 
applied relevant rights are exhausted after the first sale of the good in any 
market and it means that parallel trade is allowed43. 
In any case and according to the above mentioned, what should be taken into 
consideration is the fact that the main scope of European Union Law provisions is the 
establishment and functioning of a single EU internal market, according to Articles 34, 
35 and 36 of the Treaty on the Functioning of the European Union. As a result, this is 
why the implementation of the principle of free movement of goods is more important 
than the exercise of Intellectual Property Rights, meaning that in cases where there is 
regional exhaustion of Intellectual Property Rights, there is no conflict with the 
proprietor of the intellectual property rights for the free movement of the goods in 
European Union. Ιn other words, in the framework of EU single internal market no 
Intellectual Property Right shall be exercised if it harms or even prohibits the free 
movement of consumer goods in European Union. However, there is an exemption 
regarding Article 36 of the Treaty on the Functioning of the European Union which 
applies in specific and few cases. Depending on the above mentioned, parallel trade 
started expanding in European Union and EU law cases are trying until today to 
execute the principle of free movement of goods in any case44. 
                                                 
43 See Arfwedson Jacob, “Re-importation (Parallel Trade) in Pharmaceuticals”, Institute for Policy Innovation (IPI 
Center for Technology Freedom, 2004) 5 
44 Health Christopher, “Parallel imports and international trade” (published 1997), available at  
<http://www.wipo.int/mdocsarchives/ATRIP_GVA_99/ATRIP_GVA_99_6_E.pdf> 
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2.5. Conclusion 
To sum up, it is hereby mentioned that pallel trade in consumer goods, in general is 
something very important for the functioning of the EU inetranal market European 
Union. More specifically, last decades a very common phenomenon is parallel trade in 
pharmaceuticals within Member States, something that has to do, of course, with the 
existing circumstances in pharmaceutical market in EU. In more detail, the application 
of Directives and the establishment of European Medicines Evaluation Agency (EMEA) 
were the most important steps for the implementation of the aim of EU Internal 
Market because, in this way, pharmaceutical companies started following a certain 
authorization procedure for the whole EU Internal Market45. Finally, in this chapter 
procedure and in this way gain not only time but also money as there is no need to do 
the same procedure in different countries. Moreover, in this Chapter was mentioned 
the important meaning of intellectual rights as assets of the companies in 
pharmaceutical industry, as well as the effects of exhaustion of IPRS. 
 
 
 
 
 
                                                 
45 See Kyle Margaret, “Parallel trade in pharmaceuticals: Firm responses and competition policy” (published 2009), 
345 
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3. Restraints in Parallel trade of pharmaceuticals and Competition Law 
Provisions of EU Competition Law play a vital role in parallel trade in general, its 
purpose being to ensure the proper functioning of internal market, protecting 
simultaneously not only the companies, but, also, the consumers of the Member 
States.46  
In many cases firms around the world try to prohibit sometimes parallel importing of 
consumer goods on the basis of certain competition measures. However, in order to 
examine whether this prohibition is lawful, Articles 101 and 102 of the Treaty on the 
Functioning of the European Union should be taken into consideration.  
3.1. Article 101 TFEU 
In more detail, Article 101 TFEU is one of the most important provisions 
regarding agreements and competition measures in the framework of trade between 
Member States. The main scope of this Article is the avoidance of “..prevention, 
restriction or distortion of competition within the internal market..47”. It states that 
there should be no agreements between undertakings affecting trade between 
Member States and that these agreements are not valid. This Article of TFEU regulates 
not only many types of agreements between undertakings in Member States, but, also, 
decisions of undertakings and concerted practices, even without written agreement 
between them. Ιt is also noteworthy that this Article refers to agreements and 
practices which “..have as their object or effect the prevention, restriction or distortion 
of competition within the internal market..48” and in this way it makes distinction 
between object and effect, meaning that even when there is no object, it should be 
analysed whether the agreement or practice has similar effects. It, also, mentions in 
para (3) that there are some exemptions to Article 101 para (1) TFEU, meaning that in 
some cases the prohibition of Article 101 para (1) shall not be applied, but only under 
specific circumstances49.  One of the most important law cases, which will be analysed 
below, regarding dual pricing system is the GlaxoSmithKline Services Unlimited case, 
                                                 
46 Francesco Liberatore, “Restrictions on parallel trade of pharmaceutical products and EU Competition Law”, Ch 17 
47 Article 101 (1) TFEU 
48 Article 101 (1) TFEU 
49 See Francesco Liberatore, “Restrictions on parallel trade of pharmaceutical products and EU Competition Law”, 
Ch 17 
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known as the Spanish GSK case50. GlaxoSmithKline, one of the largest pharmaceutical 
companies in the world, informed the Commission about the system that would adopt 
regarding the differentiation of its prices in order to get the permission of Commission 
that in this way there is no infringement of Article 81 of the EC Treaty and that it falls 
within the exemption occasions of paragraph 3 of the above mentioned Article (Article 
101 TFEU now). In more detail, GlaxoSmithKline decided to sell its exported products 
in higher prices in other Member States, despite the fact that the competent 
Authorities in Spain had set a specific price for the sale of the products. Of course, the 
price for the sale of the products of the company in Spain was the one regulated by the 
Spanish governmental health authorities, but in this way GlaxoSmithKline’s practice 
reduced parallel importing to other countries. In this case, it was decided by 
Commission that GlaxoSmithKline restricted parallel importing of pharmaceutical 
products, as it infringed EU Competition Rules and foreign traders from European 
Union had to pay more for the products of GlaxoSmithKline than the Spanish 
Authorities have regulated. Further, the Court of first instance (CFI) decided that there 
was no infringement of EU Competition Law and that there should be examined which 
was the result by the GlaxoSmithKline’s practice, but after CIF’s decision, Commission 
appealed to ECJ. ECJ, finally, decided that dual pricing schemes is a restriction of 
parallel importing of products by object. However, ECJ decided that Commission 
should not come to the conclusion that dual pricing system is opposed to Article 81 of 
the EC Treaty, without taking into consideration that the effects, and examine whether 
GlaxoSmithKline’s practice would give rise to innovation, something very important for 
the pharmaceutical sector. In this way, ECJ stated that it was very important to be 
examined whether Article 81 (3) of the EC Treaty (Article 101 (3) TFEU now) could be 
applied in this case.  
3.2. Article 102 TFEU 
To continue with, Article 102 TFEU regulates monopolies that affect trade between 
Member States. Analytically, this Article, which is as important as the previously 
mentioned (Article 101) has to do with the firms around European Union that have a 
                                                 
50 Christophe Henim, “Parallel trade and pharmaceuticals in the EU: current issues”, (published 2018, Thomson 
Reuters) Cases C-501/06, C-213/06, C-515/06 and C-519/06 
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prevailing position in their sector51. Thus, as mentioned in Article 102 TFEU, 
undertakings shall not use their power wrongly, meaning that they shall not use 
abusive behaviour, unless there are specific justifications, which allow such a 
behaviour52. Οtherwise, abusive behaviour as described in the provision of this Article 
affects the competition, which is specifically regulated in EU Law provisions. Regarding 
Article 102 TFEU, there is an important law case, which will be analysed more in the 
next chapter and refers to the system of allocation. This case is known as Sot Lelos kai 
Sia EE v GlaxoSmithKline AEVE (GSK AEVE)53 and has to do with GSK AEVE, which 
suddenly, in 2000, started selling its medicinal products mainly to Greek hospitals and 
pharmacies and as a result, there was not enough quantity of products to be sold to 
Greek wholesalers as well. ECJ decided that every undertaking is lawfully able to take 
measures in order to secure its own interests in the framework of its own trade 
performance, but only if there is no aim of abusive behaviour because of a dominant 
position. Moreover, the Court of Justice claimed that what should be taken into 
account in order to examine whether there is an abuse or not in cases of allocation 
systems, is whether a wholesaler was always ordering the same quantity of products 
by the supplier and also if the quantity asked by the wholesaler is big enough in 
comparison with the general interests of the specific area of trade and as ECJ stated, 
this is an issue that should be decided by the local courts. In any case, ECJ mentioned 
that the claim of GSK AEVE that this practice is in favour of consumers is not 
acceptable and decided finally, that this practice is beneficiary for both parties. 
 
3.3. Conclusion 
To sum up, it has to be mentioned in this chapter that Competition Law provisions play 
a major role in parallel trade among Member States and help the functioning of EU 
Internal Market. However, there are many cases according to which companies, 
despite the principle of free movement of goods, try to prohibit the parallel trade of 
products between companies in European Union depending on Competition Law 
                                                 
51 Gotz Drauz “The pharmaceutical sector and competition law in Europe”, (published at MULTI-INDUSTRY) available 
at <https://www.wsgr.com/publications/PDFSearch/drauz-0312.pdf> 
52 Article 102 TFEU 
53 Christophe Henim, “Parallel trade and pharmaceuticals in the EU: current issues”, (published 2018, Thomson 
Reuters) Cases C-468/06 to C-478/06 
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measures of Articles 101 and 102 of the Treaty on the Functioning of the European 
Union, the legality of which should be examined from time to time. 
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4. Parallel trade law cases 
As analyzed in this paper, parallel trade in pharmaceuticals is a very common 
phenomenon among Member States nowadays.  The main reason why parallel trade is 
so popular in pharmaceutical sector and more specifically, in pharmaceutical 
companies around EU, is that companies can re-sell pharmaceutical products in higher 
prices, even if they bought them in Member States that due to national regulations 
have lower prices. In this way, traders make extremely high profits according to the 
European Law and the principle of free movement of goods. However, there are many 
unclear issues regarding to which there is considerable volume of Court of Justice case 
law. For example, there are many law-cases regarding the compliance of trade 
methods with EU Competition Law rules and especially with Articles 101 and 102 of 
the Treaty on the Functioning of the European Union (TFEU). Analytically, some of the 
most important issues are dual pricing schemes and supply allocation systems in the 
framework of trade of pharmaceutical products. Finally, another very important issue 
regarding parallel trade in pharmaceutical sector, is repackaging of pharmaceutical 
products, which has raised many disputes and as a result, there are many decisions 
trying to interpret related regulations54.  
4.1. Dual pricing system 
To start with, dual pricing system is a method which pharmaceutical firms 
around European Union use because of the parallel trade which takes place in this 
sector. It means that EU pharmaceutical firms have two (2) different prices for their 
medicinal products in relation to the country that they sell the products. One for the 
domestic market and one for the foreign countries, meaning a higher price for the 
other EU countries. It has been examined whether dual pricing schemes is a system 
that restricts competition between EU Member States on the basis of Article 101 TFEU.  
4.1.1. GlaxoSmithKline Services Unlimited Case 
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  One of the most important law cases regarding dual pricing system is the 
GlaxoSmithKline Services Unlimited case55, as above mentioned, known as the Spanish 
GSK case. GlaxoSmithKline, one of the largest pharmaceutical companies in the world, 
informed the Commission about the system that would adopt regarding the 
differentiation of its prices in order to get the permission of Commission that in this 
way there is no infringement of Article 81 of the EC Treaty and that it falls within the 
exemption occasions of paragraph 3 of the above mentioned Article (Article 101 TFEU 
now). In more detail, GlaxoSmithKline decided to sell its exported products in higher 
prices in other Member States, despite the fact that the competent Authorities in 
Spain had set a specific price for the sale of the products. Of course, the price for the 
sale of the products of the company in Spain was the one regulated by the Spanish 
governmental health authorities, but in this way GlaxoSmithKline’s practice reduced 
parallel importing to other countries. 
In this case, it was decided by Commission that GlaxoSmithKline restricted 
parallel importing of pharmaceutical products, as it infringed EU Competition Rules 
and foreign traders from European Union had to pay more for the products of 
GlaxoSmithKline than the Spanish Authorities have regulated. Further, the Court of 
first instance (CFI) decided that there was no infringement of EU Competition Law and 
that there should be examined which was the result by the GlaxoSmithKline’s practice, 
but after CIF’s decision, Commission appealed to ECJ. ECJ, finally, decided that dual 
pricing schemes is a restriction of parallel importing of products by object. However, 
ECJ decided that Commission should not come to the conclusion that dual pricing 
system is opposed to Article 81 of the EC Treaty, without taking into consideration that 
the effects, and examine whether GlaxoSmithKline’s practice would give rise to 
innovation, something very important for the pharmaceutical sector. In this way, ECJ 
stated that it was very important to be examined whether Article 81 (3) of the EC 
Treaty (Article 101 (3) TFEU now) could be applied in this case.  
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4.2. Supply quota system 
The supply quota system has to do with the fact that sometimes suppliers minimize 
the supply of goods and supply products only for domestic needs and not for parallel 
trade. 
4.2.1. Bayer/Adalat case 
Another very important case, in the framework of parallel trade in 
pharmaceuticals is Bayer/Adalat case56. To analyse it, this is a case regarding an 
undertaking that refused to supply its product, but this company - on the contrary of 
the previously mentioned case - was not in a dominant position. Adalat is a medicinal 
product produced by Bayer, which is sold in many Member Stated in a certain price, 
which local authorities have regulated every time. Between 1989 and 1993 the drug, 
French and Spanish authorities decided that the price of Adalat would be lower. As a 
result, and because of the fact that in UK this drug was almost 40% more expensive, 
traders from Spain and France decided to export it to UK and in this way, the sales of 
the product by the subsidiary company of Bayer established in UK  were extremely 
reduced. For this reason, Bayer stopped selling so large quantities to wholesalers from 
Spain and France, leading to the decision of Commission that Bayer behaved on the 
contrary of the provisions of Article 101 TFEU. Despite Commission’s decision, CFI 
mentioned that there was no agreement between Bayer and the wholesalers. ECJ 
agreed with CFI, a very important decision which means that, in general, suppliers of 
pharmaceutical products with no dominant position, have the ability to prevent 
parallel export of goods if there is no agreement between them and the wholesalers. 
 
4.3. Supply allocation system 
Another important issue concerning parallel trade in pharmaceuticals, is the 
system of allocation, meaning that sometimes companies limit the quantities of supply 
of their products in order to reassure that there should be enough quantities on the 
basis of the commercial interests of every undertaking. 
                                                 
56 Christophe Henim, “Parallel trade and pharmaceuticals in the EU: current issues”, (published 2018, Thomson 
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4.3.1. Sot Lelos kai Sia EE v GlaxoSmithKline AEVE (GSK AEVE) 
 Regarding allocation systems, there is a worldwide known case Sot Lelos kai Sia 
EE v GlaxoSmithKline AEVE (GSK AEVE)57. In this famous case, GSK AEVE, which was a 
subsidiary company of GlaxoSmithKline in Greece, for many years supplied many 
wholesalers in Greece. Afterwards, wholesalers were selling these pharmaceutical 
products not only in Greece, but, also, in other Member States where the prices were 
higher. Suddenly, in 2000, GSK AEVE started selling its medicinal products mainly to 
Greek hospitals and pharmacies and as a result, there was not enough quantity of 
products to be sold to Greek wholesalers as well. On the basis of the above mentioned 
practice GSK AEVE, started a legal dispute by Greek wholesalers in front of the Greek 
Courts, claiming that GSK AEVE infringed Article 82 of the EC Treaty (Article 102 TFEU 
now) in an abusive manner, because of its dominant position. The Court of Appeals in 
Greece, noticed ECJ and asked for a preliminary ruling with regards to the practice of 
GSK AEVE and whether this company was able according to the EU Law to reduce the 
supply of its products, in order to stop Greek wholesalers from exporting them to 
other Member States and gaining profit. ECJ decided that every undertaking is lawfully 
able to take measures in order to secure its own interests in the framework of its own 
trade performance, but only if there is no aim of abusive behaviour because of a 
dominant position. Moreover, the Court of Justice claimed that what should be taken 
into account in order to examine whether there is an abuse or not in cases of 
allocation systems, is whether a wholesaler was always ordering the same quantity of 
products by the supplier and also if the quantity asked by the wholesaler is big enough 
in comparison with the general interests of the specific area of trade and as ECJ stated, 
this is an issue that should be decided by the local courts. In any case, ECJ mentioned 
that the claim of GSK AEVE that this practice is in favour of consumers is not 
acceptable and decided finally, that this practice is beneficiary for both parties. 
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4.4. Repackaging procedure 
Finally, one of the most important issues in parallel trade of pharmaceuticals, 
not only in European Union, but, also, all over the world is the repackaging of goods 
which has to do with the exhaustion of intellectual property rights58.  
4.4.1. Bristol-Myers Squibb case 
For example, in one of the most known cases, Bristol-Myers Squibb case59, ECJ 
stated that there are some specific criteria which should be examined in order to 
decide whether a repackaging procedure is lawful. First of all, the repackaging process 
should take place only if it is obligatory for a certain reason and in any circumstances, 
the name of the company that did the procedure should be placed upon the package 
together with the supplier. Moreover, repackaging shall not damage the product and 
undoubtedly, the intellectual property owner, meaning the trademark owner, who 
should be informed for the repackaging process. Οn the contrary, ECJ mentioned in 
another very important case, Orifarm and Paranova v Merck Sharp and Dohme60, that 
according to EU Directive and trademark regulations61, a trademark owner cannot 
prevent the sale of a good after repackaging, because it is not possible to refer the 
company, that did the repackaging procedure, upon the new package. 
 
4.5. Conclusion 
Finally, from the above mentioned it is without doubt that the framework of parallel 
trade in pharmaceuticals will remain uncertain, until all law cases have the same 
conclusion. As we can see companies around European Union do not follow strictly the 
principles of European Union, meaning that the cases examined by ECJ are even more. 
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5. Review of the parallel importing in pharmaceuticals 
Undoubtedly, parallel trade in pharmaceuticals is a phenomenon with not only 
positive, but, also, negative aspects. In this chapter will be analysed the impact of 
parallel trade on pharmaceutical sector and will be made a prediction about the future 
of parallel trade in the future.  
5.1. Positive and negative aspects of parallel trade in pharmaceuticals 
5.1.1. Positive aspects 
Parallel trade in pharmaceuticals, which is based on the basic principle of European 
Union for the free movement of goods, has, undoubtedly, many advantages.  
To start with, parallel trade gives to the patients the opportunity to buy the essential 
for their health drugs in lower price62. For this reason, consumers, many times prefer 
to buy a drug which is parallel imported and in lower price sold, than a drug supplied in 
their own country, which is more expensive, according to the regulations of the local 
health authorities. Cheaper pharmaceutical products means, further, that the cost of 
the health insurance authorities of the Member States is lower, as they give less 
money for the reimbursement of the pharmaceutical products, which consumers buy. 
As a result, health insurance authorities of the countries gain savings, something very 
important for them63. 
Another, very important positive aspect of parallel trade of pharmaceutical products is 
the fact that it contributes to the creation and development of the internal EU Market, 
which should be a responsible and competitive environment. It means, that free 
movement of pharmaceutical products in Member States ensures an environment 
conductive to intra-brand competition that gives not only to the consumers, but, also, 
to the traders the opportunity to select which is the best and more economically 
advantageous solution to their commercial needs and interests. 
                                                 
62 European Association of Euro-Pharmaceutical Companies, “What are the benefits?”, available at < 
http://www.eaepc.org/parallel-distribution/who-gains/benefits> 
63 Claudia Desogus, “Competition and Innovation in the EU Regulation of Pharmaceuticals: The case of parallel 
trade” (published 2013) ch 1, 39-42 
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Finally, from a financial point of view, parallel trade in pharmaceuticals is a very 
economically profitable way for the countries of the manufacturers of medicinal 
products, as they earn foreign exchange through transactions with foreign countries. 
Moreover, in the framework of these transactions between Member States, there is a 
great need for new work positions around European Union, because parallel trade is a 
new field for traders and in order to be successful in the whole EU internal market, 
pharmaceutical companies should appoint experienced staff with financial and legal 
knowledge to this positions.   
5.1.2. Negative aspects 
Despite to the above mentioned, parallel trade in pharmaceuticals has many 
disadvantages as well that have to be examined by the competent authorities. 
Firstly, it is undeniable fact that parallel trade in pharmaceuticals is not of great 
advantage for the consumers around European Union. In more detail, consumers do 
not gain directly money, as in all countries the highest proportion of the cost of 
medicines is undertaken by the health security system of each country, which at last 
gain the savings.  As a result, it is without doubt that parallel importers have more 
benefits by this situation. 
To continue with, another problem due to parallel trade in pharmaceuticals is that 
sometimes manufacturers do not have enough quantity of products in order to supply 
not only foreign countries, but, also the domestic market, meaning consumers, 
pharmacies and hospitals.  
Moreover, it has to be mentioned that pharmaceutical companies have to examine 
which should be the price in every country that they do business and especially parallel 
importing of drugs. Consumers cannot afford the same prices in every country and this 
is why price discrimination is a very important issue in parallel trade. A solution could 
be that a specific drug has the same price in every country, but this is something that 
could create problems and inequality and for this reason, it has to be examined every 
time64. 
                                                 
64 Claudia Desogus, “Competition and Innovation in the EU Regulation of Pharmaceuticals: The case of parallel 
trade” (published 2013) ch 1, 39-42 
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Finally, one very important negative aspect of parallel trade in pharmaceuticals is that 
because of it, pharmaceutical companies face many times profit losses. Furthermore, 
because of that, motivations for innovation become even fewer, because as it is 
known, pharmaceutical industry depends on Research and Development (R&D), 
something which means that pharmaceutical firms shall spend not only money, but 
also a long period in order to develop qualitative new pharmaceutical products. 
However, pharmaceutical companies do not invest much money in new drugs, as they 
do not have enough profits and following that they manufacture and sell cheaper 
products of poor quality65.  
5.2. Parallel trade of pharmaceuticals in the future 
 
It is without doubt, that next years parallel trade in pharmaceuticals should remain a 
very crucial issue not only for pharmaceutical companies or consumers, but, also for 
the whole European Union. Especially, nowadays, in the midst of global economic 
crisis, with strong impact on the economy of the most Member States, parallel trade of 
pharmaceuticals gives many choices regarding the purchase of drugs. Besides, as it can 
be observed within the recent few years there have been a significant effort for the 
developing of a more specific legal and financial framework of parallel trade in 
pharmaceuticals through agreements between Member States and also, through case 
law that make more clear which are the criteria for the establishment of lawful parallel 
importing of consumer goods, and more specifically of pharmaceutical drugs. 
5.3. Conclusion 
From the above mentioned, it has to be stated that parallel trade in pharmaceuticals 
has not only advantages but also disadvantages for the whole European Union. 
Undoubtedly, the fact that patients can buy from a wide range of products in higher or 
lower prices is something important. However, the main advantage has to do with the 
health security systems that gain money, as in any case the patient pays only a small 
                                                 
65 Βart Thomas, “Parallel trade of pharmaceuticals: a review of legal, economic and political aspects”, Value in 
health(Volume ii, Number 5, 2008) 1000 
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amount when buying a pharmaceutical product. Another very important positive 
aspect of parallel trade of pharmaceutical products is the fact that it contributes to the 
development of the internal EU Market. Parallel trade in pharmaceuticals has many 
disadvantages as well, such as the fact that consumers do not make such savings as 
health systems do and that producers sometimes do not have enough quantoty of 
products. It remains to be seen which will be the circumstances in parallel trade of 
pharmaceutocals in  some yers 
.  
Conclusions 
It is without doubt that parallel trade in pharmaceuticals in European Union 
plays a vital role in the pharmaceutical sector. Parallel trade in general, and 
specifically, of pharmaceutical products is based on the general principle of the free 
movement of goods between Member States according to Articles 34, 35 and 36 TFEU. 
In any case, when parallel trade in pharmaceuticals is examined, as above stated, not 
only Intellectual Property Law provisions, but, also, Competition Law provisions should 
be taken into consideration. 
On the one hand, as analysed in this paper, parallel trade in pharmaceuticals 
has some positive aspects, meaning, for example, that consumers sometimes buy 
pharmaceutical products in lower prices or that governmental health authorities can 
have savings because of parallel trade. Moreover, parallel trade helps the function of 
internal market in European Union and ensure a competitive environment between 
Member States. However, on the other hand it is clear that the most positive effects of 
parallel trade in pharmaceuticals have to do with the parallel traders and not with the 
consumers or the Member States.  
All these years, as we can easily understand, ECJ is trying to find the best way in 
order to level out the benefits of parallel importers, consumers and pharmaceutical 
companies. However, it has been proven that this is not an easy procedure. For 
example, there are many people saying that pharmaceutical companies sometimes 
have a negative effect from parallel trade in pharmaceuticals and as a result they do no 
invest in new drugs, but prefer to take money even for the most low-quality new drug.  
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At this point, it should be mentioned which is the role of Competition Law 
provisions in parallel trade in pharmaceuticals. The law cases until today prove, more 
specifically, that Article 101 TFEU gives to pharmaceutical companies the opportunity 
to put restrictions in cross-border trade between EU Members States depending on 
Article 101 (3) TFEU that states some exemptions in the general principle of EU Law 
about prohibition of agreements between parties that in any way try to restrict 
competition between Member States. For sure, in the nearest future, pharmaceutical 
companies will most frequently try to put obstacles in parallel importing due to 
financial crisis, trying in this way to avoid loss.  
To sum up, in my opinion, according not only to the general circumstances and 
changes in pharmaceutical market in EU, but, also, to the law cases and decisions of 
ECJ, there is a general understanding of the problems of pharmaceutical companies 
around European Union, but it should be balanced with the principle of free 
movement of goods in European Union. However, it is true that competent authorities 
understand the concerns of pharmaceutical firms that face negative effects and 
financial problems because of the fact that through parallel importing other companies 
gain money despite the fact that they may have not spent money or time on Research 
and Development procedures.  The ideal scenario would be if there was a mechanism 
and the respective regulations that could protect the commercial interests of 
pharmaceutical companies without restricting parallel trade between Member States. 
Pharmaceutical companies could also lead to this direction by trying to find solutions 
according to which parallel trade and competition between Member States will not 
create problems to the commercial interests of pharmaceutical companies. For 
example, if they try to promote all the innovative drugs which they produce, they will 
give ground to competition between Member States and protect their commercial 
interests.  
In any case, the interests of patients should be always be more important than 
the interest of pharmaceutical companies and as result the patient protection and the 
principle of free circulation of goods should be the criteria for parallel trade between 
Member States in the future. 
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